RxDoctor Payments Data

Timothy Brinkman, MD

Family Medicine · McKinney, TXNPI 1821065699

Payments from drug & device makers

$5,531in general payments, 2019–2025

Across 347 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$429
  • Otsuka America Pharmaceutical, Inc.$429
  • GSK$415
  • Lilly USA, LLC$392
  • Pfizer$341
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$5,531100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,531 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$165,427
Medicare patients
404
Services billed
3,514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$73,211
JanuviaSitagliptin Phosphate35$33,804
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$18,747
FarxigaDapagliflozin Propanediol16$11,720
TradjentaLinagliptin16$10,706
Tresiba Flextouch U-100Insulin Degludec11$10,377
Breo ElliptaFluticasone/Vilanterol12$5,243
Rosuvastatin Calcium385$3,870
Levothyroxine Sodium326$3,390
SynthroidLevothyroxine Sodium53$3,348
Pravastatin Sodium154$1,923
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide66$1,791
Risedronate Sodium21$1,695
Pantoprazole Sodium91$1,558
Olmesartan Medoxomil89$1,458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$319$73,21157 claims
MerckJanuvia$179$33,80435 claims
GSKTrelegy Ellipta, Breo Ellipta$415$23,99031 claims
AstraZenecaFarxiga$429$11,72016 claims
Boehringer IngelheimTradjenta$133$10,70616 claims
AbbVieSynthroid$1,069$3,34853 claims
PfizerPaxlovid$341$1,42914 claims
Almatica Pharma LLCSertraline Hcl$16$999123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in McKinney

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →